Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03849118




Registration number
NCT03849118
Ethics application status
Date submitted
29/01/2019
Date registered
21/02/2019
Date last updated
17/05/2024

Titles & IDs
Public title
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
Scientific title
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
Secondary ID [1] 0 0
89Zr-TLX250-003
Universal Trial Number (UTN)
Trial acronym
89ZR-TLX250
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Clear Cell Renal Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Diagnosis / Prognosis - 89Zr-girentuximab

Experimental: 89Zr-girentuximab - A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.


Diagnosis / Prognosis: 89Zr-girentuximab
Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
Intervention code [1] 0 0
Diagnosis / Prognosis
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Sensitivity and Specificity of Qualitative Assessment of PET/CT Imaging With 89Zr-TLX250 to Noninvasively Detect ccRCC in Patients With Indeterminate Renal Masses, Using Histology as Standard of Truth.
Timepoint [1] 0 0
Diagnostic PET/CT scan on Day 5 ± 2 days post 89Zr-TLX250 administration. Histological confirmation of the material from nephrectomy conducted within 90 days post 89Zr-TLX250 administration served as standard of truth.

Eligibility
Key inclusion criteria
1. Written and voluntarily given Informed Consent

2. Male or female =18 years of age

3. Imaging evidence of a single indeterminate renal mass of =7cm in largest diameter
(tumour stage cT1) , on CT or MRI with and without contrast agent, suspicious for
ccRCC

4. Scheduled for lesion resection as part of regular diagnostic work-up within 90 days
from planned 89Zr-TLX250 administration

5. Negative serum pregnancy tests in female patients of childbearing potential (at
Screening and within 24 hours prior to receiving investigational product)

6. for patients included in France only, verification and confirmation of their
affiliation with a social security

7. Sufficient life expectancy to justify nephrectomy

8. Consent to practice double-barrier contraception until a minimum of 42 days after
89Zr-TLX250 administration
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Bioptic procedure (rather than a partial or total nephrectomy) planned for
histological species delineation of IRM

2. Renal mass known to be a metastasis of another primary tumour

3. Active non-renal malignancy requiring therapy during the time frame of the study
participation

4. Chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to the planned
administration of 89Zr-TLX250 or continuing adverse effects (> grade 1) from such
therapy (Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)

5. Planned antineoplastic therapies (for the period between administration of 89
Zr-TLX250 and imaging)

6. Exposure to murine or chimeric antibodies within the last 5 years

7. Previous administration of any radionuclide within 10 half-lives of the same

8. Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic)
that may interfere with the objectives of the study or within the safety of compliance
of the subjects as judged by the Investigator

9. Mental impairment that may compromise the ability to give Informed Consent and comply
with the requirements of the study

10. Exposure to any experimental diagnostic or therapeutic drug within 30 days from the
date of planned administration of 89Zr-TLX250

11. Women who are pregnant or breastfeeding

12. Known hypersensitivity to Girentuximab or DFO (Desferrioxamine)

13. Renal insufficiency with glomerular filtration rate (GFR) = 60 millilitres/min/1.73m2

14. Vulnerable patients (e.g being in detention)

Study design
Purpose of the study
Diagnosis
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/08/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/11/2022
Sample size
Target
Accrual to date
Final
300
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [2] 0 0
Macquarie University Hospital - Sydney
Recruitment hospital [3] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [5] 0 0
Austin Health - Heidelberg
Recruitment hospital [6] 0 0
Victorian Comprehensive Cancer Centre - Melbourne
Recruitment hospital [7] 0 0
Cabrini Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
2109 - Sydney
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
3000 - Melbourne
Recruitment postcode(s) [7] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Washington
Country [8] 0 0
Belgium
State/province [8] 0 0
Brussels
Country [9] 0 0
Belgium
State/province [9] 0 0
Leuven
Country [10] 0 0
Canada
State/province [10] 0 0
Quebec
Country [11] 0 0
Canada
State/province [11] 0 0
Québec
Country [12] 0 0
France
State/province [12] 0 0
Bordeaux
Country [13] 0 0
France
State/province [13] 0 0
Nancy
Country [14] 0 0
France
State/province [14] 0 0
Nantes
Country [15] 0 0
Netherlands
State/province [15] 0 0
Amsterdam
Country [16] 0 0
Netherlands
State/province [16] 0 0
Nijmegen
Country [17] 0 0
Turkey
State/province [17] 0 0
Ankara
Country [18] 0 0
Turkey
State/province [18] 0 0
Istanbul
Country [19] 0 0
United Kingdom
State/province [19] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Telix Pharmaceuticals (Innovations) Pty Limited
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal
cell carcinoma.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03849118
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Howard Gurney, MD
Address 0 0
Macquarie University Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries